Melanoma — Trials · CancerIndex

Clinical trials

Registered studies

3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 605
Recruiting: 316
Ph III recruiting: 30
Growth YoY: +37.2%
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 37.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (571)

clinicaltrialsPublishedShowing 1–50 of 258 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05764395	Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors	terminated	Phase 2	7	Vanderbilt-Ingram Cancer CenterOTHER	1	Sep 16, 2026	clinicaltrials
NCT01029873	QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma	terminated	Phase 1 / Phase 2	22	Altor BioScienceINDUSTRY	1	Sep 10, 2026	clinicaltrials